655 related articles for article (PubMed ID: 16457809)
1. Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative.
Cherng SC; Huang WH; Shiau CY; Lee AR; Chou TC
Eur J Pharmacol; 2006 Feb; 532(1-2):32-7. PubMed ID: 16457809
[TBL] [Abstract][Full Text] [Related]
2. 2-(2-Br-phenyl)-8-methoxy-benzoxazinone (HPW-RX2), a direct thrombin inhibitor with a suppressive effect on thromboxane formation in platelets.
Wu CC; Wang TW; Wang WY; Hsieh PW; Wu YC
Eur J Pharmacol; 2005 Dec; 527(1-3):37-43. PubMed ID: 16313903
[TBL] [Abstract][Full Text] [Related]
3. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase.
Liu FC; Liao CH; Chang YW; Liou JT; Day YJ
Biochem Pharmacol; 2009 Apr; 77(8):1364-73. PubMed ID: 19426675
[TBL] [Abstract][Full Text] [Related]
4. Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A2 synthesis inhibition.
Brito FC; Kummerle AE; Lugnier C; Fraga CA; Barreiro EJ; Miranda AL
Eur J Pharmacol; 2010 Jul; 638(1-3):5-12. PubMed ID: 20412790
[TBL] [Abstract][Full Text] [Related]
5. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
Hoet B; Arnout J; Deckmyn H; Vermylen J
Thromb Haemost; 1993 Nov; 70(5):822-5. PubMed ID: 8128441
[TBL] [Abstract][Full Text] [Related]
6. C-phycocyanin, a very potent and novel platelet aggregation inhibitor from Spirulina platensis.
Hsiao G; Chou PH; Shen MY; Chou DS; Lin CH; Sheu JR
J Agric Food Chem; 2005 Oct; 53(20):7734-40. PubMed ID: 16190625
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms involved in the antiplatelet effect of C-phycocyanin.
Chiu HF; Yang SP; Kuo YL; Lai YS; Chou TC
Br J Nutr; 2006 Feb; 95(2):435-40. PubMed ID: 16469164
[TBL] [Abstract][Full Text] [Related]
8. The protective effects of paclitaxel on platelet aggregation through the inhibition of thromboxane A2 synthase.
Lee JJ; Yu JY; Lee JH; Zhang WY; Kim TJ; Myung CS; Yun YP
Arch Pharm Res; 2010 Mar; 33(3):387-94. PubMed ID: 20361303
[TBL] [Abstract][Full Text] [Related]
9. Antiplatelet activity of carnosol is mediated by the inhibition of TXA2 receptor and cytosolic calcium mobilization.
Lee JJ; Jin YR; Lim Y; Hong JT; Kim TJ; Chung JH; Yun YP
Vascul Pharmacol; 2006 Sep; 45(3):148-53. PubMed ID: 16916624
[TBL] [Abstract][Full Text] [Related]
10. Antiplatelet activity of J78 (2-Chloro-3-[2'-bromo, 4'-fluoro-phenyl]-amino-8-hydroxy-1,4-naphthoquinone), an antithrombotic agent, is mediated by thromboxane (TX) A2 receptor blockade with TXA2 synthase inhibition and suppression of cytosolic Ca2+ mobilization.
Jin YR; Cho MR; Ryu CK; Chung JH; Yuk DY; Hong JT; Lee KS; Lee JJ; Lee MY; Lim Y; Yun YP
J Pharmacol Exp Ther; 2005 Jan; 312(1):214-9. PubMed ID: 15328379
[TBL] [Abstract][Full Text] [Related]
11. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.
Feijge MA; Ansink K; Vanschoonbeek K; Heemskerk JW
Biochem Pharmacol; 2004 Apr; 67(8):1559-67. PubMed ID: 15041473
[TBL] [Abstract][Full Text] [Related]
12. The antiplatelet effects of a new nitroderivative of acetylsalicylic acid--an in vitro study of inhibition on the early phase of platelet activation and on TXA2 production.
Lechi C; Andrioli G; Gaino S; Tommasoli R; Zuliani V; Ortolani R; Degan M; Benoni G; Bellavite P; Lechi A; Minuz P
Thromb Haemost; 1996 Nov; 76(5):791-8. PubMed ID: 8950792
[TBL] [Abstract][Full Text] [Related]
13. Splitomicin suppresses human platelet aggregation via inhibition of cyclic AMP phosphodiesterase and intracellular Ca++ release.
Liu FC; Liao CH; Chang YW; Liou JT; Day YJ
Thromb Res; 2009 Jun; 124(2):199-207. PubMed ID: 19327818
[TBL] [Abstract][Full Text] [Related]
14. Mechanism involved in the antiplatelet activity of naloxone in human platelets.
Sheu JR; Hung WC; Lee LW; Chang PT; Kan YC; Yen MH
Biochem Biophys Res Commun; 1997 Feb; 231(1):12-6. PubMed ID: 9070210
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet activity of Phellinus baummii methanol extract is mediated by cyclic AMP elevation and inhibition of collagen-activated integrin-α(IIb) β₃ and MAP kinase.
Kamruzzaman SM; Endale M; Oh WJ; Park SC; Kim TH; Lee IK; Cho JY; Park HJ; Kim SK; Yun BS; Rhee MH
Phytother Res; 2011 Nov; 25(11):1596-603. PubMed ID: 21394810
[TBL] [Abstract][Full Text] [Related]
16. Effects of CI-930, a novel phosphodiesterase III inhibitor, on platelet aggregation and arachidonic acid metabolism.
Chen XS; Zeng HW; Jiang YY; Wan WQ; Long K
Zhongguo Yao Li Xue Bao; 1990 Jul; 11(4):338-43. PubMed ID: 1966575
[TBL] [Abstract][Full Text] [Related]
17. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.
Muggli R; Tschopp TB; Mittelholzer E; Baumgartner HR
J Pharmacol Exp Ther; 1985 Oct; 235(1):212-9. PubMed ID: 2995647
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms involved in the antiplatelet activity of rutin, a glycoside of the flavonol quercetin, in human platelets.
Sheu JR; Hsiao G; Chou PH; Shen MY; Chou DS
J Agric Food Chem; 2004 Jul; 52(14):4414-8. PubMed ID: 15237945
[TBL] [Abstract][Full Text] [Related]
19. A noble function of BAY 11-7082: Inhibition of platelet aggregation mediated by an elevated cAMP-induced VASP, and decreased ERK2/JNK1 phosphorylations.
Lee HS; Kim SD; Lee WM; Endale M; Kamruzzaman SM; Oh WJ; Cho JY; Kim SK; Cho HJ; Park HJ; Rhee MH
Eur J Pharmacol; 2010 Feb; 627(1-3):85-91. PubMed ID: 19913011
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of inhibition of platelet aggregation by HCL-31D.
Chou TC; Li CY; Lee AR; Wu TM
Eur J Pharmacol; 2000 Jan; 387(2):125-31. PubMed ID: 10650152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
